
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is positioned for continued success with its diverse portfolio of products in the growing areas of neuroscience, cardiometabolic, cancer, and immunology. The company's strong performance and potential VC investments set them apart from competitors, with a focus on innovation and addressing global challenges. With their commitment to sustainability and strong financial stability, Eli Lilly is a strong choice for investors looking for long-term growth potential.
Bears say
Eli Lilly is a well-established pharmaceutical company with a diverse portfolio of products in several therapeutic areas. However, the increased competition in the pharmaceutical industry and potential threats from generics and biosimilars could impact Lilly's key products and overall revenue growth. Additionally, the company's reliance on a few key drugs for a significant portion of its revenue could leave it exposed to potential setbacks in research and development or regulatory challenges. Furthermore, despite its recent positive financial performance and raised guidance, the company's high valuation and potential for underperformance compared to its peers may make it a risky investment.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares